TB-500 Research Peptide

Peptora Compound Research Library

TB-500 Research Peptide Overview

TB-500 Research Peptide literature concerns an acetylated short peptide related to the actin-binding region of thymosin beta-4. Analytical studies have identified TB-500 as Ac-LKKTETQ, while research surrounding thymosin beta-4 and its active peptide sequences has examined actin biology, cell migration, angiogenesis and experimental tissue-repair processes.

Research Library Commonly Studied Peptides Testing & COAs Research Peptides

Compound overview

TB-500 Research Peptide: What Is TB-500?

TB-500 is associated with a short peptide sequence derived from the central actin-binding region of thymosin beta-4, but TB-500 and full-length thymosin beta-4 should not be treated as identical research materials.

Analytical characterization published in Drug Testing and Analysis identified the material described as TB-500 as an N-terminally acetylated version of thymosin beta-4 residues 17–23: Ac-LKKTETQ.

Full-length thymosin beta-4, by comparison, contains 43 amino acids and has a broader biological research literature.

TB-500 vs Thymosin Beta-4

TB-500: analytical studies have identified it as the acetylated seven-amino-acid sequence Ac-LKKTETQ.

Thymosin beta-4 (Tβ4): a naturally occurring 43-amino-acid peptide with multiple functional regions, including an actin-binding domain containing the LKKTETQ sequence.

This distinction is essential when interpreting scientific papers because findings involving full-length Tβ4 cannot automatically be attributed to TB-500.

Sequence research

TB-500 Research Peptide and the LKKTETQ Sequence

The sequence LKKTETQ corresponds to residues 17–23 of thymosin beta-4 and lies within its central actin-binding region.

Research examining active sites within Tβ4 has identified this region as important to its interaction with actin and has investigated short sequences containing this motif in cell migration, angiogenesis and experimental wound-repair models.

Seven Residues

The TB-500 sequence identified analytically contains seven amino-acid residues: LKKTETQ.

N-Terminal Acetylation

The characterized TB-500 material contains artificial acetylation at the N-terminus, producing Ac-LKKTETQ.

Tβ4 Region

LKKTETQ corresponds to residues 17–23 within the larger thymosin beta-4 sequence.

Actin biology

TB-500 Research Peptide and Actin-Binding Research

Actin is a major structural protein involved in the cytoskeleton, cell shape and cell movement. Thymosin beta-4 is widely studied as an actin-binding peptide and a major intracellular G-actin-sequestering molecule.

The LKKTETQ region is located within the actin-binding domain of Tβ4. Earlier peptide-mimetic research identified the related LKKTET motif as a major contact region involved in interaction with actin.

G-Actin

Full-length thymosin beta-4 binds monomeric G-actin and participates in regulation of the cellular actin pool.

Cellular Movement

Because cytoskeletal actin is central to cell movement, Tβ4 and its active sequences have been investigated in migration-related experimental models.

Scientific distinction: the well-established actin-sequestering behaviour of full-length thymosin beta-4 should not automatically be assigned in its entirety to the shorter acetylated TB-500 sequence.

Cell migration

TB-500 and Cell-Migration Research

Cell migration is one of the major experimental themes surrounding thymosin beta-4 and its active peptide regions.

Research into short Tβ4 sequences has reported biological activity associated with the central actin-binding region, including experimental effects on cell migration.

This area is relevant to tissue-repair research because movement of epithelial, endothelial and other cell types is part of the complex sequence of events occurring during tissue remodelling.

Cell Migration Is a Research Endpoint

Cell-migration assays can reveal whether a compound alters cellular movement under defined laboratory conditions.

Such findings do not independently demonstrate that a research peptide repairs an injury or produces a particular outcome in humans.

Tissue models

TB-500 Research Peptide and Tissue-Repair Research

Much of the interest surrounding TB-500 originates from the broader tissue-repair literature involving thymosin beta-4 and peptide sequences derived from its actin-binding region.

In animal research published in 2003, full-length Tβ4 and a synthetic seven-amino-acid peptide corresponding to its actin-binding domain were studied in dermal wound models. The short LKKTETQ peptide produced experimental repair-related effects in aged mice in that study.

However, that work investigated the unacetylated LKKTETQ sequence. TB-500 has been analytically characterized as Ac-LKKTETQ, making it important not to describe the materials as chemically identical.

Evidence context: findings involving full-length Tβ4 or unacetylated LKKTETQ provide mechanistic background for TB-500 research, but they do not establish identical biological activity for Ac-LKKTETQ.

Angiogenesis

Thymosin Beta-4, TB-500 and Angiogenesis Research

Angiogenesis—the formation of new blood vessels—is another recurring area within the thymosin beta-4 literature.

Tβ4 has been investigated in endothelial-cell migration, vascular development and angiogenic experimental models. Research into active peptide sites has also associated sequences containing the central LKKTETQ region with angiogenesis-related activity.

Endothelial Research

Thymosin beta-4 has been studied in endothelial-cell biology and experimental vascular-development pathways.

Active Peptide Regions

Short sequences containing the Tβ4 actin-binding region have been investigated for selected angiogenesis-related biological activity.

These observations remain research findings and should not be converted into claims that TB-500 provides a clinical vascular or tissue-repair benefit.

Metabolism research

TB-500 Research Peptide and Metabolite Research

More recent research has examined TB-500 itself rather than relying entirely on data from full-length thymosin beta-4.

A 2024 analytical study investigated Ac-LKKTETQ and its metabolites using human serum, enzyme systems and rat samples. The researchers identified several metabolites and examined the parent peptide and metabolites in fibroblast wound-healing assays.

Notably, the authors reported that the parent TB-500 did not reproduce all of the biological activity often attributed to it. In their assay, the metabolite Ac-LKKTE showed significant wound-healing activity compared with control, leading the researchers to propose that some reported activity could involve metabolism rather than the parent peptide itself.

Why Metabolites Matter

A peptide can be enzymatically shortened or otherwise transformed after exposure to biological systems.

If a metabolite has different biological activity from the original material, experiments must distinguish the parent compound from the products formed during metabolism.

Evidence interpretation

Understanding the TB-500 Research Evidence

TB-500 is a good example of why closely related peptides should not be collapsed into a single evidence category.

Research Material	Structure / Description	Evidence Context
Thymosin beta-4	Native 43-amino-acid peptide	Extensive actin, cell-migration, angiogenesis and tissue-repair research
LKKTETQ	Seven-residue Tβ4 sequence, residues 17–23	Studied as part of the central actin-binding region and in experimental repair models
TB-500	N-terminally acetylated Ac-LKKTETQ	Analytically characterized; direct biological evidence is more limited
TB-500 metabolites	Shorter products formed during metabolism	Recent research suggests some metabolites may display biological activity distinct from the parent compound

For this reason, a study involving Tβ4, LKKTETQ or a TB-500 metabolite should be identified according to the actual material investigated rather than being described simply as a “TB-500 study.”

Research limitations

TB-500 Research Peptide: What the Evidence Does Not Establish

Although TB-500 is frequently discussed alongside thymosin beta-4, direct human evidence for TB-500 itself remains limited.

A recent review of peptides used in sports and musculoskeletal contexts described TB-500 among unapproved peptides for which rigorous human safety evidence is scarce. That reinforces the need to separate experimental findings from established clinical evidence.

✓ Tβ4 findings are not automatically TB-500 findings.

✓ Animal results are not proof of human effects.

✓ Cell assays are mechanistic evidence.

✓ Metabolites may behave differently from parent TB-500.

✓ Research literature does not establish dosing.

✓ Research findings do not establish clinical safety.

Analytical documentation

TB-500 Research Peptide: Purity, Identity and Batch Testing

The structural distinction between TB-500 and full-length thymosin beta-4 makes material identity especially important when evaluating a laboratory research batch.

Published literature about TB-500 does not establish the analytical characteristics of a specific supplied batch. Researchers should therefore evaluate documentation associated with the applicable lot.

✓ Confirm the stated peptide identity.

✓ Match documentation to the applicable batch.

✓ Review purity where reported.

✓ Review identity testing where reported.

✓ Review measured content where reported.

✓ Identify the analytical methods used.

✓ Review additional tests only where documented.

✓ Never transfer one batch's results to another.

For the broader analytical framework, read Peptide Purity & Certificates of Analysis (COAs) Explained and review Peptora's Testing & COAs.

Related research

TB-500 and BPC-157 Research

TB-500 and BPC-157 are often grouped together in research-material discussions, but they are structurally distinct peptides with separate scientific literatures.

The future BPC-157 Research Peptide Overview examines BPC-157 independently, while the planned BPC-157 + TB-500 Blend Research Overview will explain how the two compounds are discussed together without implying that evidence for one can be transferred to the other.

Research principle: combining two research materials does not create evidence for the combination. Each compound's literature and any evidence involving the blend itself must be evaluated separately.

Research network

Continue Exploring TB-500 and Related Research

This overview connects TB-500 with Peptora's broader educational network covering individual compounds, blends, peptide testing, stability and batch-specific documentation.

Related Peptide Research Resources

Continue into related compound overviews and foundational research education.

Commonly Studied Research Peptides in Canada → BPC-157 Research Peptide Overview → BPC-157 + TB-500 Blend Research Overview → Peptide Blends Explained → What Are Research Peptides? → Understanding Peptide Stability → Peptide Purity & COAs Explained → Complete Research Library →

TB-500 FAQ

TB-500 Research Peptide: Frequently Asked Questions

Common research questions about TB-500, thymosin beta-4, Ac-LKKTETQ, actin binding and experimental tissue-repair research.

What is the TB-500 research peptide?

Analytical studies have identified TB-500 as an N-terminally acetylated seven-amino-acid peptide, Ac-LKKTETQ, related to residues 17–23 of thymosin beta-4.

Is TB-500 the same as thymosin beta-4?

No. Full-length thymosin beta-4 contains 43 amino acids. TB-500 has been analytically characterized as the shorter acetylated sequence Ac-LKKTETQ derived from its central actin-binding region.

What does LKKTETQ mean in TB-500 research?

LKKTETQ is a seven-amino-acid sequence corresponding to residues 17–23 within thymosin beta-4 and forms part of its central actin-binding region.

Why is actin important in TB-500 research?

Thymosin beta-4 is an important actin-binding peptide, and the LKKTETQ region lies within its actin-binding domain. Actin is central to cytoskeletal organization and cell movement.

Has TB-500 been studied in tissue-repair research?

Much of the background literature concerns full-length thymosin beta-4 or unacetylated LKKTETQ. Direct biological research on acetylated TB-500 is more limited, so these materials should be distinguished when interpreting results.

Are TB-500 metabolites scientifically important?

Potentially. A 2024 study identified several TB-500 metabolites and reported activity for the metabolite Ac-LKKTE in a fibroblast wound-healing assay, highlighting the importance of distinguishing parent peptide from metabolites.

Does TB-500 have established human clinical effects?

Direct rigorous human evidence for TB-500 itself is limited. Findings from thymosin beta-4 studies, cell experiments and animal models should not be presented as established human clinical effects of TB-500.

Does published TB-500 research verify a specific research batch?

No. Scientific literature describes research involving defined materials. A specific laboratory batch must be evaluated using the analytical documentation associated with that batch.

Research use only

TB-500 Research Peptide for Controlled Laboratory Research

This overview provides educational information about TB-500, thymosin beta-4 and related peptide sequences investigated in published scientific literature. Findings involving Tβ4, cell systems, animal models or related peptide fragments should not be interpreted as established clinical effects of TB-500.

Peptora Peptide Labs research products are intended solely for controlled non-clinical laboratory research. They are not intended for human or veterinary consumption, compounding or clinical use. Nothing on this page provides medical advice, dosing or administration guidance, or representations concerning diagnosis, treatment, cure or prevention of disease.